Altimmune to Participate in the Citizens Life Sciences Conference

GlobeNewswire

昨天

Altimmune logo.png

GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:

Conference:	Citizens Life Sciences Conference
Date/Time:	Wednesday, May 7, 2025, at 9:30 a.m. EDT

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Media Contact:
Jason Spark
Inizio Evoke, Biotech
Phone: 619-849-6005
Jason.spark@canalecomm.com

This press release was published by a CLEAR® Verified individual.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2531035763"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531035763\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531035763?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 19:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2531035763","market":"us","top_or_hot":-1,"title":"Altimmune to Participate in the Citizens Life Sciences Conference","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/.RvPvvOJIdYQphH9gg6d9w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009\" title=\"Altimmune logo.png\" vspace=\"5\"/>\n<p>GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/ALT\">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:<br/></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Conference:</strong></td>\n<td>Citizens Life Sciences Conference</td>\n</tr>\n<tr>\n<td><strong>Date/Time:</strong></td>\n<td>Wednesday, May 7, 2025, at 9:30 a.m. EDT</td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n</tbody>\n</table>\n<p>The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.</p>\n<p><strong>About Altimmune<br/></strong>Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease.  For more information, please visit www.altimmune.com.</p>\n<p><strong>Follow @Altimmune, Inc. on </strong><strong>LinkedIn</strong><br/><strong>Follow @AltimmuneInc on </strong><strong>Twitter</strong><br/></p>\n<p><strong>Company Contact:</strong><br/>Greg Weaver<br/>Chief Financial Officer<br/>Phone: 240-654-1450<br/>ir@altimmune.com<br/><br/><br/><br/></p>\n<p><strong>Investor Contact:</strong><br/>Lee Roth<br/>Burns McClellan<br/>Phone: 646-382-3403<br/>lroth@burnsmc.com<br/><br/><br/><br/></p>\n<p><strong>Media Contact:</strong><br/>Jason Spark<br/>Inizio Evoke, Biotech<br/>Phone: 619-849-6005<br/>Jason.spark@canalecomm.com<br/><br/><br/><br/></p>\n<p>This press release was published by a CLEAR® Verified individual.</p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune to Participate in the Citizens Life Sciences Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune to Participate in the Citizens Life Sciences Conference\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2025-04-30 19:30</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/.RvPvvOJIdYQphH9gg6d9w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009\" title=\"Altimmune logo.png\" vspace=\"5\"/>\n<p>GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/ALT\">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:<br/></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Conference:</strong></td>\n<td>Citizens Life Sciences Conference</td>\n</tr>\n<tr>\n<td><strong>Date/Time:</strong></td>\n<td>Wednesday, May 7, 2025, at 9:30 a.m. EDT</td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n</tbody>\n</table>\n<p>The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.</p>\n<p><strong>About Altimmune<br/></strong>Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease.  For more information, please visit www.altimmune.com.</p>\n<p><strong>Follow @Altimmune, Inc. on </strong><strong>LinkedIn</strong><br/><strong>Follow @AltimmuneInc on </strong><strong>Twitter</strong><br/></p>\n<p><strong>Company Contact:</strong><br/>Greg Weaver<br/>Chief Financial Officer<br/>Phone: 240-654-1450<br/>ir@altimmune.com<br/><br/><br/><br/></p>\n<p><strong>Investor Contact:</strong><br/>Lee Roth<br/>Burns McClellan<br/>Phone: 646-382-3403<br/>lroth@burnsmc.com<br/><br/><br/><br/></p>\n<p><strong>Media Contact:</strong><br/>Jason Spark<br/>Inizio Evoke, Biotech<br/>Phone: 619-849-6005<br/>Jason.spark@canalecomm.com<br/><br/><br/><br/></p>\n<p>This press release was published by a CLEAR® Verified individual.</p>\n<br/></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/altimmune-participate-citizens-life-sciences-113000648.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1878469433.USD","symbol_name":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/altimmune-participate-citizens-life-sciences-113000648.html","article_id":"2531035763","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531035763","pubTimestamp":1746012600,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter. This press release was published by a CLEAR Verified individual.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK4599":"减肥药","BK4139":"生物科技","ALT":"Altimmune, Inc."},"translate_title":"Altimmune将参加公民生命科学会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":0.9},"content_text":"GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:\n\n\n\nConference:\nCitizens Life Sciences Conference\n\n\nDate/Time:\nWednesday, May 7, 2025, at 9:30 a.m. EDT\n\n\n \n \n\n\n\nThe session will be webcast and can be accessed by visiting the Events section of the Altimmune website.\nAbout AltimmuneAltimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease.  For more information, please visit www.altimmune.com.\nFollow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter\nCompany Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@altimmune.com\nInvestor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com\nMedia Contact:Jason SparkInizio Evoke, BiotechPhone: 619-849-6005Jason.spark@canalecomm.com\nThis press release was published by a CLEAR® Verified individual.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}